The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | LATE-POD study: ibrutinib improves PFS in younger patients with R/R MCL experiencing late relapse
Carlo Visco, MD, University of Verona, Verona, Italy, shares the findings of the LATE-POD study, an observational study investigating the impact of ibrutinib therapy on younger patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who experience their first relapse 24 months post-diagnosis. Dr Visco describes the improved progression-free survival (PFS) observed in patients receiving ibrutinib compared to chemoimmunotherapy (CIT), and further comments on the favorable outcomes observed with the use of the R-BAC (rituximab, bendamustine and cytarabine) regimen. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
